Category: Accesswire

Moderna will continue to lead clinical development and manufacturing for mRNA-3927

Moderna to receive up to $160 million in upfront and near-term development and regulatory milestones, in addition to commercial and sales milestones and tiered royalties on net sales

CAMBRIDGE, MA / ACCESS Newswire / January 29, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced a strategic collaboration with Recordati to advance Moderna’s investigational propionic acidemia (PA) therapeutic, mRNA-3927, through the final stages of clinical development and, upon approval, global commercialization. Recordati, based in Milan, Italy, is an international pharmaceutical group that provides treatments across specialty and primary care, and rare diseases, including PA. Through this agreement, Moderna will continue to lead the clinical development of mRNA-3927 through approval and Recordati will lead commercialization.

“We are proud to partner with Recordati in a joint mission to improve the lives of people living with propionic acidemia,” said Stéphane Bancel, Chief Executive Officer of Moderna. “Recordati brings deep rare disease commercial expertise and an established global commercial infrastructure in propionic acidemia that will help us accelerate the benefit of mRNA-3927 upon approval.”

“Propionic acidemia is a serious rare disease with a significant unmet medical need due to the lack of disease modifying treatment options to date. We look forward to partnering with Moderna,” said Rob Koremans, Chief Executive Officer of Recordati. “Their experience in applying innovative mRNA technology, combined with our experience in rare metabolic disorders and strong established commercial infrastructure, positions us well to advance this potential therapy together to serve patients. We are encouraged by the clinical data and look forward to the pivotal readout expected in 2026. This deal strengthens our development portfolio and builds on our heritage in the metabolic field.”

Under the terms of the agreement, Moderna will receive an upfront payment of $50 million and up to an additional $110 million in near-term development and regulatory milestones, in addition to commercial and sales milestones and tiered royalties on net sales. The transaction is subject to customary closing conditions, including U.S. antitrust clearance which is expected within 30 days from the relevant filing.

mRNA-3927 is currently being evaluated in a registrational study that has reached target enrollment. The Company expects a potential data readout in 2026.

About propionic acidemia (PA)

Propionic acidemia is a rare, serious, inherited metabolic disorder with significant morbidity and mortality, affecting 1 in 100,000-150,000 individuals worldwide. PA is caused by pathogenic variants in the propionyl-coenzyme A carboxylase (PCC) α or β subunits (PCCA and PCCB genes, respectively), leading to PCC deficiency and subsequent accumulation of toxic metabolites. PA is characterized by recurrent life-threatening metabolic decompensation events (MDEs) and multisystemic complications. Currently, there are no effective therapies for PA that target the underlying root cause of the disease.

About mRNA-3927

mRNA-3927 is an investigational novel mRNA-based therapeutic agent that is composed of two mRNAs encoding for normal human PCCA and PCCB subunits. Intravenous (IV) administration of mRNA-3927 is intended to restore functional PCC enzymes in patients with PA.

Interim data from a first-in-human, phase 1/2, open-label, dose optimization study and extension study evaluating the safety and efficacy of mRNA-3927 indicate early signs of potential clinical benefit and demonstrate that mRNA-3927 has infrequent treatment-limiting side effects.

About Moderna

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna’s mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s collaboration with Recordati to commercialize its PA therapy; Moderna’s clinical development of mRNA-3927; timing of an expected pivotal data readout in 2026; the potential for regulatory approval and commercialization of mRNA-3927; potential payments, milestones and royalties under the collaboration agreement; and expected closing of the transaction and customary closing conditions, including U.S. antitrust clearance. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

Beloved New Children’s Book Where Are You Going, Sammy Snail? by Author Jennifer Schwipps. A beautifully told springtime story celebrating friendship and mindfulness is now available for families and classrooms, quickly finding its place among favorite read-alouds.

NAPERVILLE, IL / ACCESS Newswire / January 29, 2026 / Author and illustrator Jennifer Schwipps has officially released her new picture book, Where Are You Going, Sammy Snail?, a visually rich and thoughtfully paced story that invites young readers and their families to slow down, notice the world around them, and savor the value of companionship.

Ideal for preschoolers and early readers, the book offers a calm, reassuring reading experience and makes a natural addition to both home and classroom libraries.

A Timely Story in a Fast-Paced World

Where Are You Going, Sammy Snail? follows Sammy, a thoughtful snail traveling through a bright spring meadow in search of his “special spot.” Along the way, he meets two new friends, Timothy Turtle and Cathy Caterpillar. Through gentle encounters and shared moments, the story captures the joy of discovery and connection.

A Lesson in Friendship
Sammy invites Timothy and Cathy to join him on his journey. When Timothy Turtle accidentally tips onto his back, Sammy and Cathy work together to help him turn over, highlighting themes of kindness, cooperation, and care.

The Power of Slowing Down
Sammy’s special spot turns out to be a cool, shaded place beneath an oak tree, where the air feels lighter and the moss resembles a soft blanket. What makes the place truly special is not the location itself, but the fact that Sammy shares it with his friends on the first day of spring.

Mindfulness and Nature
The story gently encourages children to notice the small details of the natural world, from the scent of clover and the sound of a babbling brook to the colors of wildflowers across the meadow. It is a nature-centered narrative that invites calm attention and curiosity.

“I wanted to create a peaceful reading experience for children growing up in a noisy world,” says Jennifer Schwipps. “This book is about slowing down, paying attention, and connecting with nature and with each other.”

Unique Features That Engage Families

The book has quickly found a place among gentle read-alouds and bedtime favorites, offering a soothing narrative free from harsh language or overstimulation.

A Family Affair
The illustrations are a collaborative effort by Jennifer Schwipps, Amanda Schwipps-Allison, and Benjamin Schwipps, reflecting a shared, intergenerational creative process.

Interactive Fun
The final pages invite children to draw their favorite character or imagine a new animal Sammy might invite to his special place, encouraging creativity and storytelling beyond the page.

Classroom Ready
Educators note that the book pairs naturally with spring-themed lessons and supports classroom discussions around friendship, emotions, and seasonal change.

Where Are You Going, Sammy Snail? is now available for purchase online and through major book retailers.

Media Contact

• Dan Wasserman

• PR@evrimachicago.com

^Disclaimer

• ^{This is a critical opinion-based cultural analysis authored by Waa Say and reflects his personal editorial perspective. The views expressed do not represent the institutional stance of Evrima Chicago.}

• ^{This article draws from open-source information, legal filings, published interviews, and public commentary – including audio content from The Joe Rogan Experience podcast. All allegations referenced remain under investigation or unproven in a court of law.}

• ^{No conclusion of criminal liability or civil guilt is implied. Any parallels made to public figures are interpretive in nature and intended to examine systemic patterns of influence, celebrity, and accountability in American culture.}

• ^{Where relevant, satirical, rhetorical, and speculative language is used to explore public narratives and their societal impact. Readers are strongly encouraged to engage critically and examine primary sources where possible.}

• ^{This piece is protected under the First Amendment of the U.S. Constitution and published under recognized standards of opinion journalism.}

• ^{Evrima Chicago remains committed to clear distinction between fact-based reporting and individual editorial perspective.}

SOURCE: Author J. Schwipps

View the original press release on ACCESS Newswire

New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support future clinical programs

GelrinC is set to transform cartilage repair market with off-the-shelf regenerative products

HERZLIYA, ISRAEL / ACCESS Newswire / January 29, 2026 / Regentis Biomaterials Ltd., (“Regentis” or the “Company”) (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced the expansion of its U.S. clinical site network, further strengthening its infrastructure to support its ongoing pivotal Phase III study of GelrinC^® for knee cartilage repair as well as future clinical programs.

“Building on our existing clinical collaborations, we are adding several new, highly regarded academic and clinical orthopedic centers to our network,” stated Dr. Ehud Geller, Executive Chairman of Regentis. “This expansion is designed to further accelerate patient enrollment, increase the efficiency of our clinical strategy, leverage leading orthopedic expertise, and generate robust clinical data to support product development and future commercialization efforts following our company’s recent IPO.”

GelrinC^® is approved for knee cartilage repair in the European Union and is currently at midpoint in a pivotal FDA trial for the same indication to address a U.S. market of more than 470,000 potential cases annually.

The expanded clinical site network brings together leading orthopedic surgeons and institutions with strong experience in cartilage repair, joint preservation, and sports medicine, ensuring high-quality clinical execution and data generation.

Among the Participating Clinical Sites Being Added Are:

NYU Langone Orthopedic & Sports Medicine, New York, NY

A world-class academic orthopedic center consistently ranked among the top programs in the United States, known for surgical excellence and innovation. Dr. Laith Jazrawi is a leading authority in cartilage repair and joint preservation, bringing extensive academic leadership and clinical trial experience.

The Ohio State University Wexner Medical Center, Columbus, OH

A premier academic health system with a high-volume orthopedic department and strong translational research capabilities. Dr. David Flanigan is an internationally recognized surgeon-scientist specializing in knee reconstruction and cartilage restoration.

University of Cincinnati Medical Center, Cincinnati, OH

A respected academic medical center integrating advanced orthopedic care with outcomes-driven research. Dr. Brian Grawe is known for his expertise in cartilage preservation and rigorous clinical research methodology.

Loyola Medicine Orthopedic, Maywood, IL

An academic clinical program emphasizing innovation in joint preservation and participation in multicenter clinical studies. Dr. John Miller contributes deep clinical insight in cartilage and meniscal pathology.

Tulane University School of Medicine – Orthopedics, New Orleans, LA

A distinguished academic institution with a long history of impactful musculoskeletal research and interdisciplinary collaboration, providing strong academic depth and research infrastructure.

UNC Orthopedics, University of North Carolina, Chapel Hill, NC

A nationally recognized academic orthopedic department with a strong focus on clinical research and outcomes science. Prof. Joe Hart brings leadership in musculoskeletal research and experience in joint preservation studies.

Rush University Medical Center, Chicago, IL

A top-tier academic medical center widely recognized for orthopedic innovation and evidence-based care. Dr. Adam Yanke is a leading expert in cartilage regeneration and knee preservation, contributing both surgical and research excellence.

About GelrinC

Regentis’ lead product, GelrinC^®, is a cell-free, off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful injuries to focal articular knee cartilage. As an innovative regenerative medical product, GelrinC offers an unprecedented solution that gives surgeons and payers an off-the-shelf, ready to use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery, sustained pain relief, and functional improvement for more than 4 years, based on clinical study results to date. No effective off-the-shelf, ready to use treatment for focal knee cartilage defects is currently available on the market. GelrinC has CE Mark approval in the European Union and is now being evaluated in a pivotal U.S. Food and Drug Administration (FDA) study, which has completed over 50% enrollment.

About Regentis Biomaterials

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

Forward Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words, and include beliefs regarding the expansion of the Company’s clinical site network. Forward-looking statements are based on Regentis’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the ability of our clinical trials to demonstrate safety and efficacy of GelrinC or any future product candidate, and other positive results; the timing and focus of our preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for of GelrinC or any future product candidate, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to accurately identify demand for product candidates; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our ability to obtain FDA approval for of GelrinC or any future product candidate and obtain and maintain regulatory approval; our ability to obtain market acceptance of of GelrinC or any future product candidate from the medical community and third-party payors; our plans relating to the further development of GelrinC or any future product candidate, including additional disease states or indications we may pursue; existing regulations and regulatory developments in the United States and other jurisdictions; our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our dependence on third parties; our financial performance and our ability to repay our loans and debts; and our ability to negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations. For a more detailed description of the risks and uncertainties affecting Regentis, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the section titled “Risk Factors” in the final prospectus related to the public offering filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Regentis undertakes no duty to update such information except as required under applicable law.

Contact:

acarlquist@medicavp.com

SOURCE: Regentis Biomaterials Ltd

View the original press release on ACCESS Newswire

Deal underscores the firm’s accelerating presence in the HVAC/plumbing and home services sectors

PHILADELPHIA, PA / ACCESS Newswire / January 29, 2026 / Commonwealth M&A, LLC, a premier full-service Merger & Acquisition advisory firm providing transactional and valuation services to small and medium-sized businesses, has announced the acquisition of its client Phoenix Mechanical by Northwinds Services Group.

Phoenix has been delivering top-of-the-line cooling, heating and plumbing services to New York’s Westchester County area since 1996 and is a trailblazer in the Westchester Green Energy revolution. Co-owners Doug Budney and Jonathan Nissman have cultivated a skilled team of technicians with a combined experience of over 100 years, spanning from the early days of heating and cooling to today’s cutting-edge technology.

As the business nears its 30th anniversary, Budney and Nissman decided that bringing in a partner could help the company continue to prosper and also address personal milestones with Budney entering retirement and Nissman staying on board as a partner to the buyer.

Commonwealth M&A assesses every seller’s goals and expectations to develop a strategic and individualized plan, combining human understanding with real results. The team’s expertise in the HVAC and plumbing space, while being able to tactfully determine what both co-owners needed from an offer, made them the perfect advisors for the deal.

“Of course, every seller wants a competitive offer, but beyond the numbers, this process was deeply personality- and mission-driven. The Commonwealth M&A team handled that with exceptional care and intention. They approached this transaction as if it were their own business for sale, balancing strategy, relationships, and long-term outcomes in a way that truly mattered to me. I felt supported, understood, and confidently guided every step of the way, and for that, I can’t thank them enough.”

“Selling your business is one of the most important decisions an owner can make, so we were honored that Doug and Jonathan trusted us as their advisors,” said Rick Calabrese, Co-Founder of Commonwealth M&A. “We help companies in any industry, but HVAC/plumbing seem to be becoming one of our niches, with the sale of Phoenix marking our third this year. Given our experience, we know what a buyer/seller relationship needs to be successful for home services companies and are confident that these two organizations are a great match. We’re excited to watch Phoenix continue to excel with Northwinds on board.”

About Commonwealth M&A, LLC

Commonwealth M&A, LLC is a full-service Merger & Acquisition advisory firm providing transactional and valuation services to small and medium sized businesses.

Commonwealth M&A offers a differentiated approach derived from the team’s diverse set of experiences. Our mission is to deliver personalized, high-quality service that exceeds expectations.

If you are a business owner looking to sell your company, Commonwealth M&A is here to help. Contact us today to learn more about our services and how we can assist you in achieving your goals. Visit us at https://commonwealthmna.com/

Media Contact:

Martina Corona
martina@notablypr.com

SOURCE: Commonwealth M&A

View the original press release on ACCESS Newswire

Expanded agreement infuses Formerra’s European healthcare polymer portfolio with life-saving Foster^® compounds.

PUTNAM, CT AND ROMEOVILLE, IL / ACCESS Newswire / January 29, 2026 / Formerra and GEON^® Performance Solutions today announced an agreement that designates Formerra as the preferred distributor of Foster^®, LLC medical compounds in Europe. This adds to Formerra’s current distribution of these materials in North and South America, enabling Formerra to now support customers who need the same product in all regions.

Following GEON’s January 2025 acquisition of Foster, the agreement builds on Formerra’s long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials.

“Bringing Foster’s medical-grade portfolio to Europe strengthens our ability to support healthcare manufacturers across the region with specialized compounds and the local expertise they need to navigate complex regulatory environments,” said Kelly Wessner, Vice President, Key Accounts, Formerra. “Building on the momentum of our Americas partnership, we’re excited to extend these proven solutions to European customers who demand the highest standards in medical device materials.”

With more than 30 years in custom medical polymer compounding, Foster delivers highly engineered, top-of-the-polymer-pyramid formulations tailored to demanding requirements. The portfolio includes options such as radiopaque compounds and grades that meet USP Class VI requirements and align with ISO 10993 expectations. These materials support critical end uses across the healthcare space, including implantable products and other highly specialized applications.

“Extending our Foster portfolio into Europe with Formerra allows us to meet growing demand from healthcare manufacturers in one of the world’s most dynamic medical device markets,” said Arthur Adams, Chief Commercial Officer, GEON. “This expansion reinforces our shared commitment to supporting innovation in life-saving applications globally.”

Adding Foster^® compounds to its European portfolio will enable Formerra to better serve customers in the healthcare space, offering not only access to highly engineered medical polymers, but also deep regulatory expertise and responsive logistics across the region.

Formerra will exhibit at MD&M West in Booth 2266 in Anaheim, California, February 3-5, 2026.

###

Key Details

• Formerra will distribute Foster^® medical compounds in Europe.

• This agreement adds custom medical-grade compounds to Formerra’s existing global access to GEON^® PVC and filled PP materials.

About Formerra
Formerra is a preeminent distributor of engineered materials, connecting the world’s leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways – driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.

About GEON Performance Solutions
GEON^® Performance Solutions unlocks the power of polymers for the future. From biomedical materials from our medical division, Foster, LLC, to building materials, automotive, connectivity, and appliances, customers in these markets rely on the portfolio of compounding solutions, highly adaptable vinyl, polyolefin, engineered resin technologies, and full-service contract manufacturing that we deliver. In every formulation, collaboration, and challenge we’re shaping the brilliance of tomorrow and providing a formidable advantage by engineering what’s possible. Geon has approximately 1,200 global associates and 15 world-class manufacturing plants with headquarters in Westlake, Ohio. Learn more at www.geon.com. Geon is a portfolio company of SK Capital Partners.

Media Contact
Jackie Morris
Marketing Communications Manager, Formerra
jackie.morris@formerra.com
+1 630-972-3144

SOURCE: Formerra

View the original press release on ACCESS Newswire

Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical industry, from pre-clinical development to full-scale GMP commercial manufacturing.

ESTERO, FLORIDA / ACCESS Newswire / January 29, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted, patent-pending drug delivery technology, today announced it has entered into an agreement with Microsize (Quakertown, Pennsylvania), the largest independent North American contract development and manufacturing organization (CDMO) focused on cGMP micronization and particle size engineering.

Microsize specializes in particle size reduction, micronization, and solubility enhancement for drugs. Aspire has partnered with Microsize to support the ongoing development of its lead drug candidate: acetylsalicylic acid (aspirin) 162 mg sublingual powder, an investigational new drug undergoing development for the emergency treatment of suspected acute myocardial infarction (heart attack).

This collaboration is expected to deliver optimized drug product to support an upcoming clinical trial and the planned submission of a Section 505(b)(2) New Drug Application for Aspire’s sublingual aspirin near the end of 2026.

The clinical trial will evaluate serum thromboxane B₂ (TxB₂) inhibition in 32 healthy volunteers, comparing (162 mg) against the current standard of care-two chewed 81 mg aspirin tablets. This collaboration marks a critical step for Aspire, securing critical expertise to support its ongoing and future product development and regulatory efforts.

CEO Commentary

“We value Microsize’s special expertise and are excited to partner with the Microsize team to support development of our sublingual aspirin product as we prepare to submit a New Drug Application later this year,” said Kraig Higginson, Interim CEO of Aspire. “This agreement is a critical step in our path forward, and reinforces our commitment to excellence, product quality, and U.S.-based innovation.”

This agreement builds upon Aspire’s broader strategy to develop existing, approved therapeutics that offer faster onset of action with fewer side effects.

About Microsize

For over 30 years, Microsize has been a pioneer in enhancing dissolution and bioavailabilty of Active Pharmaceutical Ingredients (API’s) and functional excipients via particle size reduction technologies including milling, micronization and classification. Operating from 100,000 square feet in US-based, state-of-the-art, FDA inspected GMP facilities, Microsize has the experience and capabilities to rapidly develop, scale up, and process API’s and excipients ranging from grams to multi-metric tons, including highly potent compounds. Microsize is the partner of choice from small biotechs to big pharma to CDMO’s, and is recognized for its speed, responsiveness, and high customer-touch business model. Visit www.microsize.com.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning small molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; Aspire’s acetylsalicylic acid sublingual powder, 162 mg (OTASA) is an investigational new drug and has not been approved for marketing for any indication, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

Composites manufacturing expert, RAMPF Composite Solutions, selected to build the main body of the Cavorite X7

TORONTO, ONTARIO / ACCESS Newswire / January 29, 2026 / New Horizon Aircraft Ltd. (NASDAQ:HOVR), doing business as Horizon Aircraft (“Horizon Aircraft” or the “Company”), an advanced aerospace engineering company and developer of one of the world’s first hybrid-electric VTOL (Vertical Take-Off and Landing) aircraft, announces it has partnered with RAMPF Composite Solutions (“RAMPF”) to manufacture the fuselage (the main body of the aircraft) for the Cavorite X7.

RAMPF has earned a strong global reputation as a leader in high-performance composite design, engineering, and manufacturing. By combining advanced manufacturing processes with premium composite materials, RAMPF meets the most demanding industry standards. With deep experience supporting aerospace and defense customers, RAMPF will manufacture a fuselage for the Cavorite X7 that optimizes its performance by meeting precise requirements for the aircraft. These requirements include the fuselage being made of lightweight and high-strength composite materials to improve fuel efficiency and durability; designed to withstand harsh conditions, temperature fluctuations, and high-impact forces; and have high structural integrity and precision.

RAMPF Composite Solutions CEO Larry Fitzgerald had this to say about the announcement. “We are very excited to work with Horizon Aircraft on their revolutionary new aircraft, the Cavorite X7. This is the kind of project that professionals across the composites industry truly aspire to work on. It will show how lightweight, high‑performance composites continue to push the boundaries of engineering and design. It is an honour for RAMPF to collaborate with Horizon on such a game-changing aircraft.”

Horizon Aircraft Co-Founder and CEO Brandon Robinson stated, “RAMPF’s industry-leading aerospace composite capabilities make this a critical partnership for us. Seeing fuselage manufacturing underway is incredibly meaningful, and having it built locally in Ontario, Canada is something we are proud of. RAMPF’s highly experienced team understands the significance of what Horizon Aircraft is working to achieve, and we look forward to bringing the Cavorite X7 to life together.”

For more information about Horizon Aircraft, please see the Company’s website or watch its innovative technology in action on the Company’s YouTube channel.

About Horizon Aircraft

Horizon Aircraft (NASDAQ:HOVR) is an advanced aerospace engineering company that is developing one of the world’s first hybrid-electric VTOL (Vertical Take-Off and Landing) aircraft designed to fly most of its mission in traditional wing-borne flight, offering industry-leading speed, range, and operational utility. Horizon Aircraft’s unique designs put the mission first and prioritize safety and performance. Upon successful completion of testing and certification of its full-scale aircraft, Horizon Aircraft intends to scale unit production to meet expected demand from regional operators, emergency service providers, and military customers.

For further information, visit:

Website www.horizonaircraft.com
LinkedIn https://www.linkedin.com/company/horizon-aircraft-inc

About RAMPF Composite Solutions

RAMPF Composite Solutions, Inc. based in Burlington, Ontario, Canada, is a leading expert in the manufacture of carbon fiber and fiberglass composites parts for the aerospace, defense, consumer products, and medical industries. RAMPF Composite Solutions redefines composite manufacturing through advanced processes that deliver lightweight, high-strength components while minimizing waste and reducing cost.

The company’s comprehensive composite manufacturing services include VARTM, resin infusion, tailored fiber placement (TFP), precision tooling, metallization, and full subassembly. Each process is designed to ensure tight tolerances, repeatable quality, and scalable production, helping composite manufacturers maintain a competitive edge across industries.

From aerospace-grade composites to high-volume industrial parts and custom prototypes, RAMPF Composite Solutions stands as a trusted composite parts manufacturer in North America – delivering quality, speed, precision, and cost savings.

RAMPF Composite Solutions is a company of the international RAMPF Group based in Grafenberg, Germany.

For further information, contact:

Investors:

Kathryn Burns
ir@horizonaircraft.com

Media:

Edwina Frawley-Gangahar
EFG Media Relations
+44 7580 174672
edwina@efgmediarelations.com

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “aim,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “target,” “will be,” “will continue,” “will likely result” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements herein include, but are not limited to, statements relating to the targeted readiness of the full-scale hybrid Cavorite X7 eVTOL prototype for initial testing, development priorities and technical milestones; funding and liquidity sufficiency and runway; certification and testing plans; and potential production, partnership, supply chain and market opportunities.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) changes in the markets in which Horizon Aircraft competes, including with respect to its competitive landscape, technology evolution or regulatory changes; (ii) the risk that Horizon Aircraft will need to raise additional capital to execute its business plans, which may not be available on acceptable terms or at all; (iii) the lack of useful financial information for an accurate estimate of future capital expenditures and future revenue; (iv) statements regarding Horizon Aircraft’s industry and market size; (v) financial condition and performance of Horizon Aircraft, including the condition, liquidity, results of operations, the products, the expected future performance and market opportunities of Horizon Aircraft; (vi) Horizon Aircraft’s ability to develop, certify, and manufacture an aircraft that meets its performance expectations; (vii) successful completion of testing and certification of Horizon Aircraft’s Cavorite X7 eVTOL; (viii) the targeted future production of Horizon Aircraft’s Cavorite X7 aircraft; and (ix) other factors detailed by us in the Company’s public filings with the Securities and Exchange Commission (“SEC”) and under the Company’s profile on sedarplus.ca, including the disclosures under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2025, filed with the SEC and filed under the Company’s profile on sedarplus.ca on August 22, 2025. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made.

Readers are cautioned not to put undue reliance on forward-looking statements, and while the Company may elect to update these forward-looking statements at some point in the future, it assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by applicable law. Horizon Aircraft does not give any assurance that Horizon Aircraft will achieve its expectations.

SOURCE: Horizon Aircraft

View the original press release on ACCESS Newswire